Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bone Biologics Corp (NQ: BBLG )

1.190 -0.100 (-7.75%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Bone Biologics Corp

Bone Biologics Appoints Phillip T. Meikle to its Board of Directors
From Bone Biologics
Via Business Wire
Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Bone Biologics Corporation
Via Business Wire
Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
From Bone Biologics Corporation
Via Business Wire
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
First Two Patients Treated in Pilot Clinical Study with Bone Biologics’ NB1 Bone Graft Device in Spine Fusion
From Bone Biologics Corporation
Via Business Wire
Life Sciences Virtual Investor Forum Agenda Announced for June 20th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
Bone Biologics Executives to be Interviewed in a “CEO Chat” by Zacks Small-Cap Research Analyst on June 20th
From Virtual Investor Conferences
Via GlobeNewswire
Bone Biologics Announces Closing of $2.0 Million Public Offering
From Bone Biologics Corporation
Via Business Wire
Bone Biologics Announces Pricing of $2.0 Million Public Offering
From Bone Biologics Corporation
Via Business Wire
Bone Biologics Reports Progress With NB1 Clinical Program
From Bone Biologics Corporation
Via Business Wire
Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors
From Bone Biologics Corporation
Via Business Wire
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
From Bone Biologics Corporation
Via Business Wire
Bone Biologics Announces 1-for-8 Reverse Stock Split
From Bone Biologics Corporation
Via Business Wire
Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Bone Biologics Corporation
Via Business Wire
Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Bone Biologics Corporation
Via Business Wire
Bone Biologics Provides Scientific Update on NB1 Bone Graft Device
From Bone Biologics
Via Business Wire
BioMedNewsBreaks – Bone Biologics Corporation (NASDAQ: BBLG) Announces $5M Underwritten Public Offering
Via Investor Brand Network
Bone Biologics Prices $5.0 Million Underwritten Public Offering
From Bone Biologics Corporation
Via Business Wire
Bone Biologics Effects 1-for-30 Reverse Stock Split
From Bone Biologics Corporation
Via Business Wire
Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia
From Bone Biologics Corporation
Via Business Wire
Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization
From Bone Biologics Corporation
Via Business Wire
Bone Biologics CEO Issues Letter to Stockholders
From Bone Biologics Corporation
Via Business Wire
Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering
From Bone Biologics Corporation
Via Business Wire
CORRECTING and REPLACING Bone Biologics Prices $5,100,000 Underwritten Public Offering
From Bone Biologics Corporation
Via Business Wire
Bone Biologics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
From Bone Biologics Corporation
Via Business Wire
Bone Biologics to Present at the H.C. Wainwright BioConnect Virtual Conference
From Bone Biologics Corporation
Via Business Wire
Bone Biologics Corp. Announces Closing of Public Offering and Uplisting to Nasdaq
From Bone Biologics Corp.
Via Business Wire
Bone Biologics Corp. Announces Pricing of $7.9 million Public Offering; Uplisting to the Nasdaq Capital Market and Reverse Stock Split
From Bone Biologics Corp.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.